Royal College of Surgeons in Ireland
Browse
Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants.pdf (905.49 kB)

Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants

Download (905.49 kB)
journal contribution
posted on 2024-04-29, 15:51 authored by Georgios N Stamatas, Takahiro Sato, Carol Ní Chaoimh, Thierry Oddos, Richard Insel, Jonathan HourihaneJonathan Hourihane, Alan D Irvine

Background: The Short-Term Topical Application for Prevention of Atopic Dermatitis (STOP AD) study, a randomized, open-label trial evaluating the effect of short-term (from the first 4 postnatal days to age 8 weeks) skin barrier protection using Aveeno Dermexa Fast & Long-Lasting Balm (Johnson & Johnson, New Brunswick, NJ) in infants with a parent with allergic disease, demonstrated decreased cumulative incidence and decreased prevalence of atopic dermatitis (AD) at age 12 months.

Objective: In the STOP AD study, we aimed to identify skin biomarkers that are associated with risk of development of AD.

Methods: Skin swabs were collected from the cheek and antecubital fossa (AF) at baseline, age 8 weeks, and age 12 months from subsets of study participants from the intervention arm (n = 43 of 119) and control arm (n = 43 of 138) and were analyzed for specific cytokines (CCL27, CXCL2, human β-defensin-1 [hBD-1], IL-18, IL-8, IL-1α, IL-1 receptor antagonist [IL-1RA], IL-1β, S100A8/9, and IL-36γ) by ELISA.

Results: Higher titers of S100A8/9 at the AF at age 8 weeks in infants with the filaggrin wild-type genotype (FLGwt), but not in those with filaggrin loss-of-function mutation (FLGmut), predicted (1) development of AD in the first year of life (P = .033), (2) presence of AD at ages 6 or 12 months (P = .009 and .035, respectively), (3) persistence of AD between ages 6 and 12 months (P < .001), and (4) development of AD with the emollient intervention.

Conclusion: Increased titers of S100A8/9 from skin swabs of the AF in high-risk infants at age 8 weeks with FLGwt were predictive of AD development in the first year of life and other AD features. These findings suggest that there are different molecular pathways leading to AD in individuals with FLGmut and in individuals with FLGwt. Early identification of infants who are likely to develop AD will allow more targeted interventions.

Funding

City of Dublin Skin and Cancer Hospital Charity

Janssen R&D

Johnson & Johnson Santé Beauté France

History

Comments

The original article is available at https://www.jacionline.org/

Published Citation

Stamatas GN. et al. Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants. J Allergy Clin Immunol. 2024:S0091-6749(24)00234-3.

Publication Date

7 March 2024

PubMed ID

38460678

Department/Unit

  • Paediatrics

Publisher

Elsevier

Version

  • Published Version (Version of Record)